Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma

• Published in: Future oncology (London, England) Vol. 20; no. 6; p. 317
• Main Authors: Garg, Mahek, Puckett, Justin, Kamal-Bahl, Sachin, Raut, Monika, Ryland, Katherine Elizabeth, Doshi, Jalpa A, Huntington, Scott F
• Format: Journal Article
• Language: English
• Published: England 01-02-2024
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Health Resources; Humans; Lymphoma, Large B-Cell, Diffuse - drug therapy; Medicare; Retrospective Studies; Rituximab - therapeutic use; United States - epidemiology; United States; costs; diffuse large B-cell lymphoma; Medicare; elderly; survival; treatment patterns
• ISSN: 1744-8301
• DOI: 10.2217/fon-2023-0191

To examine real-world treatment patterns, survival, healthcare resource use and costs in elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL).
11,880 Medicare patients aged ≥66 years with DLBCL between 1 October 2015 and 31 December 2018 were followed for ≥12 months after initiating front-line treatment.
Two-thirds (61.2%) of the patients received standard-of-care R-CHOP as first-line treatment. Hospitalization was common (57%) in the 12-months after initiation of 1L treatment; the mean DLCBL-related total costs were US$84,416 during the same period. Over a median follow-up of 2.1 years, 17.8% received at least 2L treatment. Overall survival was lower among later lines of treatment (median overall survival from initiation of 1L: not reached; 2L: 19.9 months; 3L: 9.8 months; 4L: 5.5 months).
A large unmet need exists for more efficacious and well-tolerated therapies for older adults with DLBCL.